NASDAQ: BCTX
Briacell Therapeutics Corp Stock Ownership - Who owns Briacell Therapeutics?

Insider buying vs selling

Have Briacell Therapeutics Corp insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Marc LustigDirector2024-05-14902,935$2.22
$2.00MBuy

1 of 1

BCTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when BCTX insiders and whales buy or sell their stock.

BCTX Shareholders

What type of owners hold Briacell Therapeutics Corp stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Marc Lustig112.76%4,182,935$17.94MInsider
Jamieson Bondarenko4.58%169,856$728.68kInsider
Williams V. Williams4.03%149,636$641.94kInsider
Vontobel Holding Ltd2.97%110,000$471.90kInstitution
Group One Trading LLC1.83%67,885$291.23kInstitution
Cantor Fitzgerald L P1.51%56,000$240.24kInstitution
Susquehanna International Group LLP1.36%50,609$217.11kInstitution
Onyx Bridge Wealth Group LLC1.35%50,000$214.50kInstitution
Virtu Financial LLC1.31%48,663$208.76kInstitution
Ubs Group Ag1.07%39,606$169.91kInstitution

1 of 3

BCTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
BCTX13.00%87.00%Net Buying
CING1.20%98.80%Net Selling
UBX18.84%52.24%Net SellingNet Selling
KAPA2.44%40.42%Net Buying
LPCN5.80%94.20%

Briacell Therapeutics Stock Ownership FAQ

Who owns Briacell Therapeutics?

Briacell Therapeutics (NASDAQ: BCTX) is owned by 18.19% institutional shareholders, 121.73% Briacell Therapeutics insiders, and 0.00% retail investors. Marc Lustig is the largest individual Briacell Therapeutics shareholder, owning 4.18M shares representing 112.76% of the company. Marc Lustig's Briacell Therapeutics shares are currently valued at $17.53M.

If you're new to stock investing, here's how to buy Briacell Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.